\n\n
default-sum-open-background-color<\/div>
default-sum-close-background-color<\/div>
true<\/div>
default-sum-open-hover-color<\/div>
default-sum-open-focus-color<\/div>
default-sum-close-focus-color<\/div>
.default-sum-close-hover-color<\/div>
Authorized for emergency use in the treatment of COVID-19<\/strong><\/h1><\/summary>\n\n- LAGEVRIO\u2122 (molnupiravir) has not been approved, but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA), for the treatment of adults with mild-to-moderate COVID-19, who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.<\/li>
- The emergency use of LAGEVRIO is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (“the Act”), 21 U.S.C. \u00a7 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.<\/li><\/ul><\/div>\n<\/div><\/details><\/div>\n<\/div><\/div><\/div>\n\n\n\n\n\n\n\n<\/div>\n\n\n\n\n
Learn about our coupon offer<\/strong>
for LAGEVRIOTM<\/sup> (molnupiravir)<\/strong><\/h2><\/div>\n\n\n\n
\n\n
- LAGEVRIO\u2122 (molnupiravir) has not been approved, but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA), for the treatment of adults with mild-to-moderate COVID-19, who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.<\/li>
- The emergency use of LAGEVRIO is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (“the Act”), 21 U.S.C. \u00a7 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.<\/li><\/ul><\/div>\n<\/div><\/details><\/div>\n<\/div><\/div><\/div>\n\n\n\n\n\n\n\n<\/div>\n\n\n\n\n
Learn about our coupon offer<\/strong>
for LAGEVRIOTM<\/sup> (molnupiravir)<\/strong><\/h2><\/div>\n\n\n\n
![\"\"](\"https:\/\/www.lagevrio.com\/patients\/wp-content\/uploads\/sites\/107\/2026\/02\/transparent-336x300-1.png\"){kind=spacer}